163 related articles for article (PubMed ID: 23979447)
21. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
22. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
Italiano A; Massard C; Bahleda R; Vataire AL; Deutsch E; Magné N; Pignon JP; Vassal G; Armand JP; Soria JC
Ann Oncol; 2008 Apr; 19(4):787-92. PubMed ID: 18042834
[TBL] [Abstract][Full Text] [Related]
24. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
Chen TT
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
[TBL] [Abstract][Full Text] [Related]
25. Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor.
Takimoto R; Miyashita T; Mizukoshi E; Kamigaki T; Okada S; Ibe H; Oguma E; Naitoh K; Yasumoto K; Makita K; Tomita K; Goto S
Cytotherapy; 2020 Jun; 22(6):329-336. PubMed ID: 32303429
[TBL] [Abstract][Full Text] [Related]
26. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
27. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
28. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects.
Plana D; Fell G; Alexander BM; Palmer AC; Sorger PK
Nat Commun; 2022 Feb; 13(1):873. PubMed ID: 35169116
[TBL] [Abstract][Full Text] [Related]
29. A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.
Creemers JHA; Lesterhuis WJ; Mehra N; Gerritsen WR; Figdor CG; de Vries IJM; Textor J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34059522
[TBL] [Abstract][Full Text] [Related]
30. Some statistical considerations in the clinical development of cancer immunotherapies.
Huang B
Pharm Stat; 2018 Feb; 17(1):49-60. PubMed ID: 29098766
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
32. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
33. New late-emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials.
Boher JM; Filleron T; Bunouf P; Cook RJ
Stat Med; 2023 May; 42(12):1981-1994. PubMed ID: 37002623
[TBL] [Abstract][Full Text] [Related]
34. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
[TBL] [Abstract][Full Text] [Related]
35. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
36. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Master VA; Bilen MA
Cancer; 2020 Feb; 126(3):575-582. PubMed ID: 31648379
[TBL] [Abstract][Full Text] [Related]
37. Exact, distribution free confidence intervals for late effects in censored matched pairs.
Daniel SR
Biom J; 2009 Feb; 51(1):31-44. PubMed ID: 19219909
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; Master VA; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Bilen MA
Invest New Drugs; 2019 Dec; 37(6):1198-1206. PubMed ID: 30725388
[TBL] [Abstract][Full Text] [Related]
39. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS; Burns D; Kiff C; Lee D
Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]